Peptide Functionalization of Silicon for Detection and Classification of Prostatic Cells
Open Access
- 30 August 2017
- journal article
- research article
- Published by Wiley in Journal of Sensors
- Vol. 2017, 1-9
Abstract
The development of simple, rapid, and low cost methods for early detection, identification, and measurement of multiple biomarkers remains a challenge to improve diagnosis, treatment monitoring, and prognosis of cancer. Biosensing technology, combining the properties of biological systems with functional advanced materials, guarantees rapid, reproducible, and highly sensitive cell detection. In this study, we developed silicon-based biochips for prostate cancer PC3 cells detection by using cytokeratin 8/18 and Urotensin Receptor (UTR) as markers in order to obtain a biochip-based diagnostic system. Spectroscopic ellipsometry and fluorescence microscopy were used to characterize surface homogeneity and chemical properties. Cell detection was investigated by optical microscopy. Moreover, synthetic fluorescently labeled peptides were prepared and used for developing faster and lower-cost identification assay compared with classic ELISA immunoassay. Results showed an effective immobilization of PC3 cells on silicon surface and the specific recognition of these cells by fluorescent Urotensin II (4–11). In conclusion, this strategy could be really useful as diagnostic system for prostate cancer.Keywords
This publication has 24 references indexed in Scilit:
- Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomesNanomedicine: Nanotechnology, Biology and Medicine, 2011
- PC3 is a cell line characteristic of prostatic small cell carcinomaThe Prostate, 2011
- Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cellsJournal of Cellular Biochemistry, 2010
- Proteomic Analysis of Conditioned Media from the PC3, LNCaP, and 22Rv1 Prostate Cancer Cell Lines: Discovery and Validation of Candidate Prostate Cancer BiomarkersJournal of Proteome Research, 2008
- Understanding the Biology of Bone Metastases: Key to the Effective Treatment of Prostate CancerClinical Cancer Research, 2008
- R115777 (Zarnestra®)/Zoledronic acid (Zometa®) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl‐2 and bad phosphorylationJournal of Cellular Physiology, 2006
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- Biosensors: recent advancesReports on Progress in Physics, 1997
- Inferring the natural time history of breast cancer: Implications for tumor growth rate and early detectionBreast Cancer Research and Treatment, 1984
- The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cellsCell, 1982